Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.3, Iss.2, 2003-04, pp. : 351-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting TNF-α for the treatment of inflammatory bowel disease

By Billiet Thomas Rutgeerts Paul Ferrante Marc Van Assche Gert Vermeire Séverine

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 75-101

Informa Healthcare

Access to resources Recommend Favorite

Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis

By Mease Philip J

Expert Opinion on Biological Therapy, Vol. 5, Iss. 11, 2005-11 ,pp. : 1491-1504

Informa Healthcare

Access to resources Recommend Favorite

BDNF and TNF-α polymorphisms in memory

By Yogeetha B. Haupt L. McKenzie K. Sutherland H. Okolicsyani R. Lea R. Maher B. Chan R. Shum D. Griffiths L.

Molecular Biology Reports, Vol. 40, Iss. 9, 2013-09 ,pp. : 5483-5490

Springer Publishing Company

Access to resources Recommend Favorite

Anti-TNF-α agents in the treatment of psoriatic arthritis

By Brandt Jan Braun Jürgen

Expert Opinion on Biological Therapy, Vol. 6, Iss. 2, 2006-02 ,pp. : 99-107

Informa Healthcare

Access to resources Recommend Favorite

Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-α and disease activity in patients with rheumatoid arthritis

By Wang Junfeng

Biomarkers, Vol. 18, Iss. 2, 2013-03 ,pp. : 155-159

Informa Healthcare

Access to resources Recommend Favorite